KNSA
Price
$37.10
Change
+$0.09 (+0.24%)
Updated
Sep 12 closing price
Capitalization
2.74B
52 days until earnings call
MDXXF
Price
$0.08
Change
-$0.00 (-0.00%)
Updated
Sep 10 closing price
Capitalization
8.42M
Interact to see
Advertisement

KNSA vs MDXXF

Header iconKNSA vs MDXXF Comparison
Open Charts KNSA vs MDXXFBanner chart's image
Kiniksa Pharmaceuticals International
Price$37.10
Change+$0.09 (+0.24%)
Volume$396.32K
Capitalization2.74B
PharmAla Biotech Holdings
Price$0.08
Change-$0.00 (-0.00%)
Volume$1K
Capitalization8.42M
KNSA vs MDXXF Comparison Chart in %
Loading...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KNSA vs. MDXXF commentary
Sep 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KNSA is a StrongBuy and MDXXF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 14, 2025
Stock price -- (KNSA: $37.10 vs. MDXXF: $0.08)
Brand notoriety: KNSA and MDXXF are both not notable
KNSA represents the Pharmaceuticals: Generic, while MDXXF is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: KNSA: 70% vs. MDXXF: 3%
Market capitalization -- KNSA: $2.75B vs. MDXXF: $8.42M
KNSA [@Pharmaceuticals: Generic] is valued at $2.75B. MDXXF’s [@Biotechnology] market capitalization is $8.42M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.68B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $101.15B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KNSA’s FA Score shows that 1 FA rating(s) are green whileMDXXF’s FA Score has 0 green FA rating(s).

  • KNSA’s FA Score: 1 green, 4 red.
  • MDXXF’s FA Score: 0 green, 5 red.
According to our system of comparison, KNSA is a better buy in the long-term than MDXXF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KNSA’s TA Score shows that 3 TA indicator(s) are bullish while MDXXF’s TA Score has 3 bullish TA indicator(s).

  • KNSA’s TA Score: 3 bullish, 4 bearish.
  • MDXXF’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, KNSA is a better buy in the short-term than MDXXF.

Price Growth

KNSA (@Pharmaceuticals: Generic) experienced а +3.89% price change this week, while MDXXF (@Biotechnology) price change was -8.21% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.26%. For the same industry, the average monthly price growth was +4.29%, and the average quarterly price growth was +53.41%.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.38%. For the same industry, the average monthly price growth was +7.84%, and the average quarterly price growth was +35.14%.

Reported Earning Dates

KNSA is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+1.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNSA($2.74B) has a higher market cap than MDXXF($8.42M). KNSA YTD gains are higher at: 87.563 vs. MDXXF (-55.562). KNSA has higher annual earnings (EBITDA): 5.98M vs. MDXXF (-1.86M). KNSA has more cash in the bank: 308M vs. MDXXF (1.25M). KNSA has higher revenues than MDXXF: KNSA (529M) vs MDXXF (421K).
KNSAMDXXFKNSA / MDXXF
Capitalization2.74B8.42M32,577%
EBITDA5.98M-1.86M-322%
Gain YTD87.563-55.562-158%
P/E Ratio740.20N/A-
Revenue529M421K125,653%
Total Cash308M1.25M24,739%
Total Debt9.77MN/A-
FUNDAMENTALS RATINGS
KNSA: Fundamental Ratings
KNSA
OUTLOOK RATING
1..100
27
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
38
SMR RATING
1..100
91
PRICE GROWTH RATING
1..100
50
P/E GROWTH RATING
1..100
29
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KNSAMDXXF
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 12 days ago
83%
Declines
ODDS (%)
Bearish Trend 16 days ago
78%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QTTB1.930.05
+2.66%
Q32 Bio
CTVA74.291.30
+1.78%
Corteva
PECO35.60-0.36
-1.00%
Phillips Edison & Company
MERC3.08-0.04
-1.28%
Mercer International
UPB17.57-0.35
-1.95%
Upstream Bio Inc

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
+0.24%
COYA - KNSA
42%
Loosely correlated
-2.58%
ABVC - KNSA
40%
Loosely correlated
+2.89%
JBIO - KNSA
37%
Loosely correlated
-0.77%
AMRN - KNSA
36%
Loosely correlated
+0.27%
CPRX - KNSA
36%
Loosely correlated
-1.38%
More

MDXXF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXXF has been loosely correlated with NICXF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXXF jumps, then NICXF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXXF
1D Price
Change %
MDXXF100%
N/A
NICXF - MDXXF
46%
Loosely correlated
N/A
ABVC - MDXXF
25%
Poorly correlated
+2.89%
ZIVO - MDXXF
23%
Poorly correlated
N/A
KNSA - MDXXF
20%
Poorly correlated
+0.24%
VYGR - MDXXF
20%
Poorly correlated
-4.57%
More